Source:http://linkedlifedata.com/resource/pubmed/id/21247767
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-1-31
|
| pubmed:abstractText |
The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1532-2653
|
| pubmed:author |
pubmed-author:AfaghiVahidV,
pubmed-author:BiggsMichael TMT,
pubmed-author:BrewerJanice MJM,
pubmed-author:BucklandMichael EME,
pubmed-author:CookRaymond JRJ,
pubmed-author:LittleNicholas SNS,
pubmed-author:McDonaldKerrie LKL,
pubmed-author:ParkinsonJonathon FJF,
pubmed-author:PayneCathy ACA,
pubmed-author:WheelerHelen RHR
|
| pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
329-33
|
| pubmed:meshHeading |
pubmed-meshheading:21247767-Adult,
pubmed-meshheading:21247767-Aged,
pubmed-meshheading:21247767-Brain Neoplasms,
pubmed-meshheading:21247767-Chemotherapy, Adjuvant,
pubmed-meshheading:21247767-Chromosomes, Human, Pair 1,
pubmed-meshheading:21247767-Chromosomes, Human, Pair 19,
pubmed-meshheading:21247767-Drug Resistance, Neoplasm,
pubmed-meshheading:21247767-Female,
pubmed-meshheading:21247767-Humans,
pubmed-meshheading:21247767-Immunohistochemistry,
pubmed-meshheading:21247767-Kaplan-Meier Estimate,
pubmed-meshheading:21247767-Loss of Heterozygosity,
pubmed-meshheading:21247767-Male,
pubmed-meshheading:21247767-Middle Aged,
pubmed-meshheading:21247767-Oligodendroglioma,
pubmed-meshheading:21247767-Prognosis,
pubmed-meshheading:21247767-Proportional Hazards Models,
pubmed-meshheading:21247767-Tumor Suppressor Protein p53,
pubmed-meshheading:21247767-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
|
| pubmed:affiliation |
Cerebral Tumour Research Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia. jparkinson@med.usyd.edu.au
|
| pubmed:publicationType |
Journal Article
|